Professional Documents
Culture Documents
Atherothrombosis, Inflammation, and Diabetes
Atherothrombosis, Inflammation, and Diabetes
7, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Science Inc. doi:10.1016/S0735-1097(03)00088-3
STATE-OF-THE-ART PAPER
Diabetes mellitus has been recognized as an independent pathophysiologic aspects underlying these two disease pro-
major cardiovascular risk factor since the publication of the cesses (Fig. 1).
first large-scale epidemiologic investigations in the 1970s
(1). There are over 100 million people worldwide with
diabetes (5% to 8% of overall population), and this number DIABETES MELLITUS,
is likely to increase significantly in the near future. Accord- ATHEROTHROMBOSIS, AND INFLAMMATION
ing to data from clinical studies, most diabetics die of The pathophysiologic process of atherosclerosis has been
cardiovascular disease, and atherothrombosis accounts for schematically summarized in several steps, each of them
about 8 of 10 of all diabetic deaths (2). Diabetes mellitus, in characterized by significant involvement of humoral and
the absence of previous cardiovascular disease, may confer a cellular inflammatory elements (5). Pathologic, angio-
risk of adverse cardiovascular events similar to that faced by graphic, and other in vivo studies have shown that diabetes
nondiabetic individuals who have already had a previous favors diffuse and accelerated progression of atherosclerosis
myocardial infarction, thus representing a “coronary risk (6). Diabetic plaques are also more commonly complicated
equivalent” and, therefore, diabetic patients should join and at greater risk of subsequent complications. Moreover,
secondary prevention programs, regardless of their cardio- diabetics who die suddenly show an increased number of
vascular history (3,4). Moreover, diabetic patients, consti- fissured atherosclerotic plaques, as compared with nondia-
tuting about 15% to 20% of patients presenting with acute betics (7). In fact, the results of angioscopic examination
coronary syndromes, are at considerably increased risk of show that diabetic patients with unstable angina have a
excess morbidity and mortality, as compared with nondia- higher incidence of plaque ulceration and intracoronary
betic patients, as diabetics’ risk of adverse events is twice thrombus formation than nondiabetic patients, and diabetic
that of nondiabetics, even in the most recent experimental plaques usually have a greater lipid core burden and a richer
or observational clinical studies. inflammatory component and are more commonly compli-
Diabetes and related metabolic diseases, such as hyper- cated by overlying thrombosis (8).
insulinemia, insulin resistance, and central obesity, are Genetic abnormalities. Several genetic abnormalities in
recognized as major contributors to cardiovascular morbid- glycemic metabolism have been associated with the devel-
ity and mortality. Interestingly, recent and compelling opment of diabetes, diabetic complications, or aspects of the
evidence has shown the significant and independent role of dysmetabolic syndrome. All of these derangements could be
systemic and coronary inflammation in the initiation, pro- also involved in atherogenesis. Transcription factors, such as
gression, and precipitation of atherothrombosis superim- peroxisome proliferator-activated receptor (PPAR)-alpha
posed on traditional risk factors (5). Given the increasing and -gamma, are now being intensively studied. Whereas
prevalence of diabetes and dysmetabolic syndrome, the PPAR-alpha primarily stimulates the beta-oxidative degra-
diffuse atherosclerotic burden of diabetics, the possible dation of fatty acids, PPAR-gamma promotes lipid storage
synergistic effect of diabetes and inflammation in athero- by regulating adipocyte differentiation. Peroxisome
sclerosis, as well as the potential for a preventive and proliferator-activated receptor-alpha is the molecular target
therapeutic benefit in the modulation of inflammation in of lipid-lowering drugs such as fibrates, and PPAR-gamma
diabetics, this review covers the basic epidemiologic and interacts with insulin-sensitizer drugs such as thiazo-
lidinediones, and they may significantly modulate athero-
From the Institute of Cardiology, Catholic University, Rome, Italy.
Manuscript received August 15, 2002; revised manuscript received October 31, genicity and inflammation. In particular, mutations in the
2002, accepted November 19, 2002. PPAR-gamma gene have recently been shown to be asso-
1072 Biondi-Zoccai et al. JACC Vol. 41, No. 7, 2003
Atherothrombosis, Inflammation, and Diabetes April 2, 2003:1071–7
Figure 1. The pathogenetic mechanisms involved in the initiation of subclinical atherosclerosis and progression to atherosclerotic clinical events in diabetic
patients include infection, inflammation, hyperglycemia, insulin resistance, dyslipidemia, and thrombosis. AGE ⫽ advanced glycation end products; CRP ⫽
C-reactive protein; HDL ⫽ high-density lipoprotein; HTN ⫽ hypertension; IL-6 ⫽ interleukin-6; LDL ⫽ low-density lipoprotein; PAI-1 ⫽ plasminogen
activator inhibitor-1; SAA ⫽ serum amyloid A protein; TF ⫽ tissue factor; TG ⫽ triglycerides; tPA ⫽ tissue-type plasminogen activator.
JACC Vol. 41, No. 7, 2003 Biondi-Zoccai et al. 1073
April 2, 2003:1071–7 Atherothrombosis, Inflammation, and Diabetes
activation appears to decrease vascular cell adhesion to atherogenic processes. It has also been hypothesized that
molecule-1 (VCAM-1) expression by activated endothelial reactive carbonyl groups may overwhelm the antioxidant
cells, thereby switching off the proatherogenic-activated mechanism of diabetic patients, leaving them unprotected
endothelium (10). Moreover, PPAR-alpha selectively to common oxidative stressors such as smoking.
downregulates human aortic smooth muscle cell secreting Advanced glycation end products (AGEP). Diabetic hy-
and proliferating activities (11). In particular, ligands of this perglycemia characteristically leads to nonenzymatic glyca-
transcription factor inhibit interleukin (IL)-1–induced pro- tion of common macromolecules, as usually assessed
duction of IL-6 and prostaglandin and expression of through hemoglobin A1c (18). Nonenzymatic macromolec-
cyclooxygenase-2 in endothelial cells. In hyperlipidemic ular glycation leads to the production of biomacromolecular
patients, fenofibrate-dependent PPAR-alpha activation de- aggregates known as AGEP. Glycated molecules as well as
creases levels of IL-6, fibrinogen, and C-reactive protein AGEP have been implicated in LDL modification, accu-
(CRP) (11). On the other hand, thiazolidinedione-activated mulation, and inflammatory activation. Oxidation of AGEP
PPARs inhibit both the proliferation and migration of seems to play an important and perhaps primary role in
vascular smooth muscle cells. In endothelial cells, the initiating and amplifying lipid oxidation, thus contributing
PPAR agonist troglitazone markedly attenuates tumor to the atherogenic profile of diabetics (19). Macromolecular
necrosis factor-alpha (TNF-alpha)–induced expression glycated complexes increase arterial intimal noncellular
of VCAM-1 and intercellular adhesion molecule-1 growth and may involve proteins, nucleic acids, and lipid
(ICAM-1), whereas apolipoprotein E-deficient mice structures. The formation of complex and less degradable
treated with troglitazone show reduced monocyte/ macromolecular aggregates and the impairment of scaven-
macrophage homing to atherosclerotic plaques (12). Finally, ger cells cause quantitative imbalances in lipid levels and
the combined activation of PPAR-alpha and -gamma abnormal vascular clearance of proatherosclerotic lipids
appears to decrease CRP-mediated production of monocyte (20). Specific receptors for AGEP have been described, and
chemoattractant protein-1 by human endothelial cells, an their modulation has shown antiatherosclerotic effects in
effect similar to that achieved by simvastatin. Moreover, mice, whereas in normal rabbits, AGEP induces endothelial
type 2 diabetic patients treated with troglitazone have VCAM-1 and ICAM-1 expression and promotes atheroma
increased levels of NF-kappa-B–inhibiting protein formation (21).
(I-kappa-B) and reduced NF-kappa-B activity, as well as Prothrombotic and antifibrinolytic abnormalities.
systemic levels of reactive oxygen species, plasminogen Diabetes has several prothrombotic effects possibly involved
activator inhibitor-1 (PAI-1), and CRP (13). Accordingly, in the initiation of atherosclerotic plaque, its progression,
the human promoter polymorphism 174 G/C of the IL-6 and complication. Diabetic rats show increased platelet
gene has been associated with an increased risk of cardio- adhesiveness and aggregability after common platelet-
vascular disease and hypertension (14). activating stimuli, such as adenosine and collagen (22).
Dyslipidemic abnormalities. Diabetics usually show de- Platelet dysfunction is probably due in part to increased
creased high-density lipoprotein (HDL) cholesterol levels catabolism of arachidonic acid and increased production of
and increased low-density lipoprotein (LDL) cholesterol thromboxanes. Diabetes is also associated with increased
and triglyceride levels. Diabetes is most often associated levels of fibrinogen, von Willebrand factor, factor VII,
with smaller, denser LDL that is more susceptible to factor VIII, platelet factor 4, and PAI-1 levels. Peroxisome
oxidation and thus has greater atherogenicity (5). Even if proliferator-activated receptor-alpha dysfunction or de-
diabetic patients with good glycemic control may have LDL creased activity seems to play a role in hyperfibrinogenemia
levels similar to or slightly lower than those of nondiabetic (11), and fibrates may determine a reduction in fibrinogen
individuals, fasting and postprandial levels of triglyceride- levels through PPAR-alpha activation. Diabetic and hyper-
rich lipoproteins, especially very-low-density lipoprotein, insulinemic patients typically exhibit increased production
are higher and those of HDL are lower than those of of PAI-1 from visceral abdominal adipocytes. Finally, it is
nondiabetics (15). In addition, glycation of LDL and other likely that elevated levels of tissue factor and PAI-1 and
lipoproteins is quite common in diabetes, thus making the reduced levels of tissue-type plasminogen activator are
lipoproteins of diabetic patients more susceptible to oxida- associated with increased IL-6 production from adipocytes
tion and more atherogenic. Finally, several clinical studies (according to the hypothesis of obesity as an inflammatory
have shown the benefit of lipid-lowering strategies in disease).
diabetics, even in cases of modestly increased or normal Dysmetabolic syndrome. The concept of dysmetabolic
cholesterol levels, and these benefits are often greater than syndrome (metabolic syndrome X or insulin resistance
those found in nondiabetic patients (16). syndrome) stands at the crossroads of hyperglycemia, overt
Oxidative stress. Diabetics have decreased antioxidant ac- type 2 diabetes mellitus, inflammation, and atherosclerosis
tivity and increased oxidative burden (17), and hyperglyce- (Fig. 2) (23). It is defined as a condition characterized at
mia increases the production of reactive oxygen species. least in part by one or more of the following: glucose
These may shift the oxidant-antioxidant balance toward intolerance, relative hyperinsulinemia, peripheral insulin
nonenzymatic oxidation of lipoproteins, thus contributing resistance, visceral or abdominal obesity, increased serum
1074 Biondi-Zoccai et al. JACC Vol. 41, No. 7, 2003
Atherothrombosis, Inflammation, and Diabetes April 2, 2003:1071–7
Figure 2. Reciprocal interplay between inflammation and diabetes mellitus in the pathogenesis of atherothrombosis, with emphasis on both the role of
inflammation in the development of overt diabetes mellitus and the proinflammatory action of hyperglycemia and insulin resistance. Potential or established
modulating agents are shown by dashed arrows. ACEi ⫽ angiotensin-converting enzyme inhibitors; ARB ⫽ angiotensin receptor blockers; PPAR ⫽
peroxisome proliferator-activated receptor.
triglyceride concentrations, hyperuricemia, microalbumin- mass index, fasting triglyceride or glucose levels, or statin
uria, hypertension, and endothelial dysfunction. All of these use (27). Moreover, a high white blood cell count was an
entities have in common the same final effect of hyperinsu- independent predictor of a worsening insulin action and the
linemia, low-grade inflammation, and metabolic dysfunc- development of type 2 diabetes in Pima Indians (28), as well as
tion. However, diabetes and the dysmetabolic syndrome in U.S. adult women (29). Increased levels of other markers of
seem to have both an independent detrimental effect on inflammation, such as sialic and orosomucoid acid, are also
cardiovascular outcomes, as shown by studies that adjusted associated with the later occurrence of diabetes (30).
for insulin levels, diabetic status, and glycemic control (24). More recently, an abundance of clinical evidence has
Hyperinsulinemia is also an independent and significant risk confirmed the pathogenetic role of inflammation in the
factor for coronary heart disease development in apparently onset of diabetes, showing that anti-inflammatory agents,
healthy subjects. The overwhelming prevalence of this such as statins (31), PPAR agonists (32), and other drugs,
syndrome has prompted the proposal of the so-called including angiotensin-converting enzyme inhibitors (33),
“thrifty gene hypothesis,” according to which in relatively may prevent or delay the onset of diabetes in high-risk
early times, the ability to store fat may have conferred subjects. Trials are currently underway to further validate
survival advantage, thus enriching ethnic groups of genes this exciting hypothesis.
facilitating fat storage without negative feedback control Role of nitric oxide (NO) in inflammation. Nitric oxide
(25). Several pathophysiologic mechanisms have been pro- has several pleiotropic functions in the vascular milieu,
posed, including abnormalities in leptin gene expression, beyond its well-known vasodilating capabilities. In vitro,
decreased activity of PPAR-alpha, and primary inflammatory NO selectively inhibits IL-1–induced VCAM-1 expression
or infective processes. Nonetheless, the concept of the dys- on endothelial cells. This inhibition is paralleled by reduced
metabolic syndrome has re-emphasized the metabolic and monocyte adhesion to endothelial monolayers. Nitric oxide
inflammatory role of adipocytes. In fact, among the several also decreases the endothelial expression of other leukocyte
cellular elements involved in vascular inflammation, adipocytes adhesion molecules (E-selectin and, to a lesser extent,
merit great interest, as dysfunction in lipid metabolism is ICAM-1) and secretable cytokines (IL-6 and -8). Molecu-
characteristic of diabetes, and as adipocytes have recently been lar assays indicate that NO represses VCAM-1 gene tran-
shown able to produce IL-6 and TNF-alpha (26). scription, in part by inhibiting NF-kappa-B (34). The
Role of inflammation in development of diabetes mellitus. expression of macrophage colony-stimulating factor in en-
Although it is plausible to accept diabetes as a trigger for dothelial cells, an important regulating factor of
vascular inflammation, the converse is also true, as substan- macrophage-derived foam cells in atherosclerotic lesions, as
tial evidence has shown that low-grade inflammation is an induced by oxidized LDL or TNF-alpha, is significantly
important pathogenetic determinant of type 2 diabetes. In downregulated by NO through inhibition of NF-kappa-B
the West of Scotland Coronary Prevention Study, increased (35). The precise mechanisms of NO-mediated NF-kappa-B
CRP levels significantly predicted the risk of later develop- inhibition are probably the induction and stabilization of
ing type 2 diabetes, and this risk was independent of body I-kappa-B-alpha.
JACC Vol. 41, No. 7, 2003 Biondi-Zoccai et al. 1075
April 2, 2003:1071–7 Atherothrombosis, Inflammation, and Diabetes
Role of cytokines and infectious agents. Experimental of eliciting host dysimmune responses through molecular
observations have demonstrated the central mechanistic mimicry (44). This may occur more often in an individual
relevance of several cytokines and chemokines networks in with greater global inflammatory burden and reactivity, as
atherosclerotic processes (5). In this regard, diabetes, insulin well as inflammatory dysfunction, such as in a diabetic.
resistance, and glucose intolerance all seem to have impor- Individuals infected with multiple pathogens such as
tant modulating effects, with global proatherosclerotic ac- herpes viruses, cytomegalovirus, Helicobacter pylori, and
tivity. At least partly as a consequence of hyperglycemia and hepatitis A virus have higher CRP levels and the greatest
imbalances in insulin homeostasis, diabetes commonly in- relative risk of coronary artery disease. Thus, pathogens
duces abnormalities in the expression and activity of various might contribute to the atherosclerotic process by promot-
cytokines and vasoactive peptides, such as TNF-alpha, ing inflammatory responses, whereas infection may promote
IL-6, angiotensin II, and endothelin-1 (36). Serum levels of vessel wall injury initiated by oxidized lipids, smoking-
TNF-alpha, IL-6, and several adhesion molecules are sig- derived oxidants, hypertensive shear, glycooxidized mole-
nificant predictors of future cardiovascular events in healthy cules, or a combination of these factors.
subjects as well as diabetics, and in diabetic patients, Among the putative cytokines involved in atherosclerosis,
increased VCAM-1 levels are independently associated with IL-6 appears to link local and systemic inflammation and
cardiovascular mortality (37). Interleukin-1 and TNF-alpha the hepatic acute-phase response, acting as a messenger
are produced by inflammatory cells in the atherosclerotic molecule, causing rises in CRP, serum amyloid A protein,
plaque and induce the release of IL-6 from several cell types, and fibrinogen, as well as a decrease in albumin. Notwith-
including smooth muscle cells. Furthermore, circulating standing the role of inflammation in diabetic atherosclero-
IL-6 stimulates the hypothalamic-pituitary-adrenal axis, sis, there is a strong and suggestive association between
activation of which is associated with central obesity, hy- typical characteristics of insulin resistance and chronic
pertension, and insulin resistance (38). Thus, it is intriguing low-grade inflammation. For instance, in nondiabetic sub-
that overweight and obese individuals have increased serum jects, levels of CRP and concentrations of the proinflam-
levels of CRP, IL-6, TNF-alpha, and leptin. Actually, it has matory cytokines IL-6 and TNF-alpha are related to obe-
been recently shown that IL-6 levels decrease in obese sity. Moreover, CRP concentrations are related to insulin
women after significant weight loss (39). resistance, as calculated from the homeostasis assessment
Hyperglycemic patients demonstrate a significant pro- model, blood pressure, HDL, and triglycerides, and to
duction of AGEP, which are specifically recognized by markers of endothelial dysfunction. Similar conclusions
inflammatory cells in atherosclerotic plaque, and induce the have been reached, even by the assessment of noncoronary
release of inflammatory cytokines. These mediators stimu- atherosclerosis, as CRP levels are partially associated with
late endothelial and smooth muscle proliferation, endothe- dysmetabolic syndrome markers and, together with them,
lial activation, and collagen overproduction, thus contribut- predict carotid artery atherosclerosis (45). These data seem
ing to plaque growth and progression. C-reactive protein, a to indicate that adipose tissue is an important determinant
nonspecific marker of inflammation that also has a direct of a low-level, chronic inflammatory state, as reflected by
inflammatory activity in atherosclerosis, has been associated levels of IL-6, TNF-alpha, and CRP, thus supporting the
for a decade with adverse cardiovascular outcomes in pa- hypothesis that such a low-level, chronic inflammatory state
tients with coronary artery disease as well as in healthy may induce insulin resistance and endothelial dysfunction
subjects (40,41). Interestingly, levels of CRP are higher in and, therefore, link the latter phenomena with obesity and
diabetics than in nondiabetics. Although elevated CRP cardiovascular disease (46).
levels in diabetics may depend on adipocyte activation or
dysfunction, an additional hypothesis is that elevation of INFLAMMATORY MARKERS,
CRP might be associated with a low-grade inflammatory
DIABETES MELLITUS, AND RISK PREDICTION
response driven by invading pathogens, as infections are
very common in diabetics (42). The role of infectious agents A decade ago, elevated systemic markers of inflammation
in the pathogenesis of atherothrombosis might indeed be were found for the first time to predict adverse events in
greater in diabetics than in nondiabetics, given the increased patients with severe unstable angina (40). Since then, the
pathogen burden and decreased defense mechanisms of the concept of predicting cardiac events by means of plasma
former. Among the putative organisms, possible culprits markers has been proposed and, at the same time, chal-
include Chlamydia pneumoniae, Helicobacter pylori, cytomeg- lenged in several studies in both primary and secondary
alovirus, and herpes simplex virus (43). Diabetes may affect prevention. These data suggest an important independent
several steps of the host-infectious organism interaction. prognostic value of CRP in predicting adverse outcomes in
Poor glycemic control may lead to excessive AGEP produc- the short- and long-term follow-up of patients presenting
tion, vascular inflammation, and increased endothelial per- with acute coronary syndromes and also in apparently
meability, thus permitting bacterial or viral infiltration and healthy individuals (47,48).
infection of fatty streaks and, later, atheromatous plaques. In consideration of the overlap between inflammatory
Moreover, micro-organisms may contain molecules capable status and diabetic derangements, some authors have also
1076 Biondi-Zoccai et al. JACC Vol. 41, No. 7, 2003
Atherothrombosis, Inflammation, and Diabetes April 2, 2003:1071–7
25. Lindeman RD, Romero LJ, Hundley R, et al. Prevalences of type 2 possible link between infection and atherosclerosis. Circulation 1999;
diabetes, the insulin resistance syndrome, and coronary heart disease in 99:1560 –6.
an elderly, biethnic population. Diabetes Care 1998;21:959 –66. 45. Blackburn R, Giral P, Bruckert E, et al. Elevated C-reactive protein
26. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble constitutes an independent predictor of advanced carotid plaques in
tumor necrosis factor receptors by human subcutaneous adipose tissue dyslipidemic subjects. Arterioscler Thromb Vasc Biol 2001;21:1962–8.
in vivo. Am J Physiol 1999;277:E971–5. 46. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein
27. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an in healthy subjects: associations with obesity, insulin resistance, and
independent predictor of risk for the development of diabetes in the endothelial dysfunction—a potential role for cytokines originating
West of Scotland Coronary Prevention Study. Diabetes 2002;51: from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972–8.
1596 –600. 47. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive
28. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, protein at discharge in patients with unstable angina predict recurrent
Tataranni PA. High white blood cell count is associated with a instability. Circulation 1999;99:855–60.
worsening of insulin sensitivity and predicts the development of type 2 48. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein:
diabetes. Diabetes 2002;51:455–61. relation to total mortality, cardiovascular mortality and cardiovascular
29. Ford ES. Leukocyte count, erythrocyte sedimentation rate, and dia- risk factors in men. Eur Heart J 2000;21:1584 –90.
betes incidence in a national sample of U.S. adults. Am J Epidemiol 49. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, the FRagmin
2002;155:57–64. during InStability in Coronary artery disease (FRISC) Study Group.
30. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation Markers of myocardial damage and inflammation in relation to
and prediction of diabetes mellitus in adults (Atherosclerosis Risk in long-term mortality in unstable coronary artery disease. N Engl J Med
Communities study): a cohort study. Lancet 1999;353:1649 –52. 2000;343:1139 –47.
31. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development 50. Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic
of diabetes mellitus: evidence for a protective treatment effect in the value of elevated C-reactive protein in unstable angina. Circulation
West of Scotland Coronary Prevention Study. Circulation 2001;103: 1999;100:1958 –63.
357–62. 51. Biasucci LM, Liuzzo G, Angiolillo DJ, Biondi-Zoccai GGL, Abbate
32. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic A, Crea F. C-reactive protein may have a different prognostic value in
beta-cell function and prevention of type 2 diabetes by pharmacolog- diabetics and non-diabetics with unstable angina (abstr). Eur Heart J
ical treatment of insulin resistance in high-risk Hispanic women. 2002;23 Suppl:171.
Diabetes 2002;51:2796 –803. 52. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a
33. The Heart Outcome Prevention Evaluation Study Investigators. Ef- potent predictor of mortality independently of and in combination
with troponin T in acute coronary syndromes: a Thrombolysis In
fects of an angiotensin-converting-enzyme inhibitor, ramipril, on
Myocardial Infarction (TIMI)-11A substudy. J Am Coll Cardiol
cardiovascular events in high-risk patients. N Engl J Med 2000;342:
1998;31:1460 –5.
145–53.
53. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB, the
34. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases
European Concerted Action on Thrombosis and Disabilities Angina
cytokine-induced endothelial activation. Nitric oxide selectively re-
Pectoris Study Group. Production of C-reactive protein and risk of
duces endothelial expression of adhesion molecules and proinflamma-
coronary events in stable and unstable angina. Lancet 1997;349:462–6.
tory cytokines. J Clin Invest 1995;96:60 –8.
54. Heeschen C, Hamm CW, Bruemmer J, Simoons ML, the Chimeric
35. Peng HB, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits 7E3 AntiPlateleT in Unstable angina REfractory to standard treat-
macrophage colony-stimulating factor gene transcription in vascular ment (CAPTURE) Investigators. Predictive value of C-reactive pro-
endothelial cells. J Biol Chem 1995;270:17050 –5. tein and troponin T in patients with unstable angina: a comparative
36. Kroder G, Bossenmaier B, Kellerer M, et al. Tumor necrosis factor- analysis. J Am Coll Cardiol 2000;35:1535–42.
alpha and hyperglycemia-induced insulin resistance. J Clin Invest 55. Bhatt DL, Chew DP, Robbins MA, et al. Elevated baseline CRP
1996;97:1471–77. levels predict death or MI in diabetic patients undergoing percutane-
37. Jager A, van Hinsbergh VW, Kostense PJ, et al. Increased levels of ous coronary intervention (abstr). J Am Coll Cardiol 2001;37 Suppl:
soluble vascular cell adhesion molecule-1 are associated with risk of 648A.
cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 56. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of
2000;49:485–91. C-reactive protein predict early complications and late restenosis after
38. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflamma- coronary angioplasty. J Am Coll Cardiol 1999;34:1512–21.
tion, obesity, stress and coronary heart disease: is interleukin-6 the 57. Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and
link? Atherosclerosis 2000;148:209 –14. long-term mortality after non–ST elevation acute coronary syndrome
39. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin-6 treated with a very early invasive strategy in 1042 consecutive patients.
are reduced in serum and subcutaneous adipose tissue of obese women Circulation 2002;105:1412–5.
after weight loss. J Clin Endocrinol Metab 2000;85:3338 –42. 58. Patti G, Di Sciascio G, D’Ambrosio A, Dicuonso G, Abbate A,
40. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of Dobrina A. Prognostic value of interleukin-1 receptor antagonist in
C-reactive protein and serum amyloid A protein in severe unstable patients undergoing percutaneous coronary intervention. Am J Cardiol
angina. N Engl J Med 1994;331:417–24. 2002;89:372–6.
41. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, 59. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein
and the risk of cardiovascular disease in apparently healthy men. and other markers of inflammation in the prediction of cardiovascular
N Engl J Med 1997;336:973–9. disease in women. N Engl J Med 2000;342:836 –43.
42. Danesh J, Collins R, Peto R. Chronic infections and coronary heart 60. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive
disease: is there a link? Lancet 1997;350:430 –6. marker of inflammation, predicts future risk of coronary heart disease
43. Libby P, Egan D, Skarlatos S. Roles of infectious agents in athero- in initially healthy middle-aged men: results from the MONItoring
sclerosis and restenosis: an assessment of the evidence and need for trends and determinants in CArdiovascular disease (MONICA) Augs-
future research. Circulation 1997;96:4095–103. burg cohort study, 1984 to 1992. Circulation 1999;99:237–42.
44. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated 61. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction
by serum antibodies to heat shock proteins of Escherichia coli and and angina in patients with severe peripheral vascular disease: predic-
Chlamydia pneumoniae: immune reactions to heat shock proteins as a tive role of C-reactive protein. Circulation 2002;105:800 –3.